Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis
Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, Pari M, Teng L, Wollenhaupt J (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 79
Pages Range: AB114-AB114
Journal Issue: 3
DOI: 10.1016/j.jaad.2018.05.484
Authors with CRIS profile
Involved external institutions
Swedish Medical Center
United States (USA) (US)
University of California, San Diego
United States (USA) (US)
Celgene Corporation
United States (USA) (US)
Toronto Western Hospital
Canada (CA)
Monash University
Australia (AU)
University of Orléans / Université d'Orléans
France (FR)
Schön Klinik Hamburg Eilbek
Germany (DE)
United States (USA) (US)
University of California, San Diego
United States (USA) (US)
Celgene Corporation
United States (USA) (US)
Toronto Western Hospital
Canada (CA)
Monash University
Australia (AU)
University of Orléans / Université d'Orléans
France (FR)
Schön Klinik Hamburg Eilbek
Germany (DE)
How to cite
APA:
Kavanaugh, A., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Lespessailles, E., Mease, P.J.,... Wollenhaupt, J. (2018). Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis. (pp. AB114-AB114).
MLA:
Kavanaugh, Arthur, et al. "Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis." 2018. AB114-AB114.
BibTeX: Download